Brokerages Set Medpace Holdings Inc (NASDAQ:MEDP) Price Target at $74.67

Share on StockTwits

Medpace Holdings Inc (NASDAQ:MEDP) has been assigned an average rating of “Buy” from the eight ratings firms that are presently covering the company, Marketbeat.com reports. Three investment analysts have rated the stock with a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company. The average 12 month price target among brokerages that have covered the stock in the last year is $74.67.

MEDP has been the subject of several analyst reports. ValuEngine downgraded Medpace from a “buy” rating to a “hold” rating in a research report on Wednesday, October 2nd. BidaskClub upgraded Medpace from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, December 24th. Finally, Zacks Investment Research downgraded Medpace from a “buy” rating to a “hold” rating in a research report on Saturday, November 2nd.

In other news, CFO Jesse J. Geiger sold 14,400 shares of the business’s stock in a transaction on Thursday, December 19th. The stock was sold at an average price of $82.00, for a total transaction of $1,180,800.00. Following the completion of the sale, the chief financial officer now owns 16,948 shares in the company, valued at $1,389,736. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Insiders own 24.20% of the company’s stock.

Several hedge funds have recently added to or reduced their stakes in the company. Ladenburg Thalmann Financial Services Inc. grew its stake in shares of Medpace by 53.9% during the second quarter. Ladenburg Thalmann Financial Services Inc. now owns 605 shares of the company’s stock worth $40,000 after purchasing an additional 212 shares during the period. Vigilant Capital Management LLC acquired a new stake in shares of Medpace during the fourth quarter worth $42,000. Marshall Wace LLP acquired a new stake in shares of Medpace during the first quarter worth $99,000. Tower Research Capital LLC TRC acquired a new stake in shares of Medpace during the second quarter worth $130,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank grew its stake in shares of Medpace by 32.4% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,848 shares of the company’s stock worth $155,000 after purchasing an additional 452 shares during the period. Institutional investors own 78.97% of the company’s stock.

Shares of NASDAQ:MEDP opened at $90.95 on Wednesday. Medpace has a 1-year low of $50.14 and a 1-year high of $92.07. The firm has a market capitalization of $3.26 billion, a PE ratio of 35.12, a PEG ratio of 2.08 and a beta of 1.50. The business’s 50 day moving average is $82.25 and its 200-day moving average is $77.25. The company has a current ratio of 0.80, a quick ratio of 0.80 and a debt-to-equity ratio of 0.07.

Medpace (NASDAQ:MEDP) last announced its quarterly earnings data on Tuesday, October 29th. The company reported $0.71 earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.71. Medpace had a return on equity of 17.06% and a net margin of 11.35%. The company had revenue of $216.20 million for the quarter, compared to analyst estimates of $217.14 million. During the same quarter last year, the firm earned $0.67 EPS. Medpace’s revenue for the quarter was up 20.6% compared to the same quarter last year. On average, sell-side analysts predict that Medpace will post 2.92 EPS for the current year.

Medpace Company Profile

Medpace Holdings, Inc, a clinical contract research organization, provides scientifically-driven outsourced clinical development services to the biotechnology, pharmaceutical, and medical device industries worldwide. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in a range of therapeutic areas.

Featured Article: How Do You Calculate Return on Equity (ROE)?

Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter.